Marnix Geukes Foppen

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba‐Hamprecht, Marnix Geukes Foppen et al. · Clinical Cancer Research · 2016 · 534 citations · Full text

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Julia Boshuizen, Louise A. Koopman, Oscar Krijgsman et al. · Nature Medicine · 2018 · 215 citations

Melanoma Heterogeneity, Axl Antibody-drug Conjugate, Drug Targeting +11

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

Kilian Wistuba‐Hamprecht, Alexander Martens, Florian Heubach et al. · European Journal of Cancer · 2017 · 109 citations

Tumor Immunology, T-cells Correlate, Cancer Immunosurveillance +10

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

Kilian Wistuba‐Hamprecht, Alexander Martens, Karin Haehnel et al. · European Journal of Cancer · 2016 · 66 citations · Full text

Cancer Immunosurveillance, Medicine, Melanoma +8

LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

John B.A.G. Haanen, M. Rohaan, T.H. Borch et al. · Annals of Oncology · 2022 · 16 citations

Cancer Immunosurveillance, Lba3 Treatment, Medicine +8